Olema Pharmaceuticals (NASDAQ:OLMA) Insider David Myles Sells 51,000 Shares

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) insider David Myles sold 51,000 shares of Olema Pharmaceuticals stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $30.46, for a total transaction of $1,553,460.00. Following the completion of the sale, the insider directly owned 551,881 shares in the company, valued at $16,810,295.26. This trade represents a 8.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Olema Pharmaceuticals Stock Performance

Shares of OLMA stock opened at $27.67 on Wednesday. The firm’s 50 day moving average is $18.58 and its 200 day moving average is $10.56. The company has a current ratio of 8.03, a quick ratio of 8.03 and a debt-to-equity ratio of 0.01. Olema Pharmaceuticals, Inc. has a 12 month low of $2.86 and a 12 month high of $36.26. The stock has a market capitalization of $1.90 billion, a P/E ratio of -14.80 and a beta of 1.87.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.05). On average, sell-side analysts anticipate that Olema Pharmaceuticals, Inc. will post -2.33 earnings per share for the current year.

More Olema Pharmaceuticals News

Here are the key news stories impacting Olema Pharmaceuticals this week:

• Negative Sentiment: Naseem Zojwalla sold 99,509 shares on Dec. 23 at an average $27.66 for ~$2.75M; holding afterward fell to 4,488 shares (a ~95.7% reduction). SEC Form 4 – Zojwalla sale 12/23/2025
• Negative Sentiment: Naseem Zojwalla sold 70,000 shares on Dec. 19 at an average $28.20 for ~$1.97M; his reported direct holding dropped ~40% after that trade. SEC Form 4 – Zojwalla sale 12/19/2025
• Negative Sentiment: Naseem Zojwalla sold 100,000 shares on Dec. 22 at an average $28.04 for ~$2.80M; his combined transactions over the week materially reduced his stake. SEC Form 4 – Zojwalla sale 12/22/2025
• Negative Sentiment: David C. Myles sold 51,000 shares on Dec. 19 at an average $30.46 for ~$1.55M, trimming his position by ~8.5%. SEC Form 4 – Myles sale 12/19/2025
• Negative Sentiment: Director Ian T. Clark sold 264,800 shares on Dec. 19 at an average $29.73 for ~$7.87M — a very large director-level disposal that can amplify market concern. SEC Form 4 – Clark sale 12/19/2025

Hedge Funds Weigh In On Olema Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the stock. Paradigm Biocapital Advisors LP increased its position in shares of Olema Pharmaceuticals by 0.4% during the third quarter. Paradigm Biocapital Advisors LP now owns 6,794,172 shares of the company’s stock valued at $66,515,000 after acquiring an additional 30,000 shares in the last quarter. Deep Track Capital LP boosted its stake in Olema Pharmaceuticals by 0.8% during the 3rd quarter. Deep Track Capital LP now owns 3,470,172 shares of the company’s stock valued at $33,973,000 after purchasing an additional 27,339 shares during the last quarter. MPM Bioimpact LLC increased its holdings in shares of Olema Pharmaceuticals by 0.6% in the 1st quarter. MPM Bioimpact LLC now owns 2,930,446 shares of the company’s stock worth $11,018,000 after purchasing an additional 17,896 shares in the last quarter. Woodline Partners LP raised its stake in shares of Olema Pharmaceuticals by 8.9% in the first quarter. Woodline Partners LP now owns 1,477,907 shares of the company’s stock worth $5,557,000 after purchasing an additional 120,428 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Olema Pharmaceuticals by 22.4% during the second quarter. Geode Capital Management LLC now owns 1,326,123 shares of the company’s stock valued at $5,650,000 after purchasing an additional 242,997 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have weighed in on OLMA. Citigroup upped their price target on shares of Olema Pharmaceuticals from $21.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, December 12th. Oppenheimer increased their target price on Olema Pharmaceuticals from $45.00 to $48.00 and gave the company an “outperform” rating in a report on Thursday, December 11th. HC Wainwright lifted their price target on Olema Pharmaceuticals from $36.00 to $45.00 and gave the stock a “buy” rating in a research note on Thursday, December 11th. The Goldman Sachs Group boosted their price objective on Olema Pharmaceuticals from $26.00 to $38.00 and gave the company a “buy” rating in a research report on Thursday, December 11th. Finally, Zacks Research raised shares of Olema Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, September 9th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Olema Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $40.50.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.